Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.67 |
| ▸ | MAG | P20916 | 7/20 | 0.62 |
| ▸ | SELL | P14151 | 1/20 | 0.60 |
| ▸ | SELP | P16109 | 1/20 | 0.60 |
| ▸ | CD22 | P20273 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277035 | 1.00 | SIGLEC7 (0.67) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL31716746 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL29405239 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL29412465 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL19922284 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL24628357 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL804936 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL12454161 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL14362275 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 | |
| SCHEMBL30001019 | 0.96 | SIGLEC7 (0.69) | SIGLEC7MAGSELLSELPCD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | claimed |
| CN-122029274-A | Cell production of oligosaccharides comprising lacto-N-trisaccharide (LN 3) | 因比奥斯公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025224348-A1 | PRODUCTION OF A MILK OLIGOSACCHARIDE MIXTURE | INBIOSE N.V. (BE) | 2025-10-30 | — | — | WO | disclosed |
| CN-118574859-A | Novel drying method for oligosaccharides | 因比奥斯公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240261420-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | SIGLEC7 4/4885MAG 450/4885SELL 714/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | SIGLEC7 3/4885MAG 539/4885SELL 459/4885 |
| US-20240261420-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | SIGLEC7 3/4885MAG 539/4885SELL 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.